FMP
Taysha Gene Therapies, Inc.
TSHA
NASDAQ
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
2.53 USD
0.07 (2.77%)
About
ceo
Mr. Sean P. Nolan
sector
Healthcare
industry
Biotechnology
website
https://www.tayshagtx.com
exchange
NASDAQ
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy tr...
CIK
0001806310
ISIN
US8776191061
CUSIP
877619106
Address
3000 Pegasus Park Drive
Phone
214 612 0000
Country
US
Employee
52
IPO Date
Sep 24, 2020
Summary
CIK
0001806310
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
877619106
ISIN
US8776191061
Country
US
Price
2.53
Beta
0.26
Volume Avg.
2.8M
Market Cap
473.16M
Shares
-
52-Week
0.5-3.89
DCF
-0.08
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-2.64
P/B
-
Website
https://www.tayshagtx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest TSHA News
It looks like there's no news available.
